The BioNTech SE ADR BNTX rallied 3.82% to $120.21 Monday, on what proved to be an all-around mixed trading session for the ...

RNA is a long, polymeric molecule, composed of four different building blocks called nucleotides. In the last decade mRNA has progressed into a promising new class of medicine, with the potential to ...

Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in ...

Scientists discover that SARS-CoV-2 spike protein remains in the brain and skull bone marrow for years post-infection, ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...

Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

I made four predictions about the stock market in 2024. The Fed indeed cut rates in Q4, but stocks didn't jump as much as I ...

University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...

The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...